PSA testing for men at average risk of prostate cancer

Armstrong, Bruce K., Barry, Michael J., Frydenberg, Mark, Gardiner, Robert A., Haines, Ian and Carter, Stacy M. (2017) PSA testing for men at average risk of prostate cancer. Public Health Research and Practice, 27 3: 2121-2121. doi:10.17061/phrp2731721


Author Armstrong, Bruce K.
Barry, Michael J.
Frydenberg, Mark
Gardiner, Robert A.
Haines, Ian
Carter, Stacy M.
Title PSA testing for men at average risk of prostate cancer
Journal name Public Health Research and Practice   Check publisher's open access policy
ISSN 2204-2091
1034-7674
Publication date 2017-07-01
Year available 2009
Sub-type Critical review of research, literature review, critical commentary
DOI 10.17061/phrp2731721
Open Access Status DOI
Volume 27
Issue 3
Start page 2121
End page 2121
Total pages 6
Place of publication Ultimo, NSW, Australia
Publisher Sax Institute
Language eng
Subject 2739 Public Health, Environmental and Occupational Health
Abstract Prostate-specific antigen (PSA) testing of men at normal risk of prostate cancer is one of the most contested issues in cancer screening. There is no formal screening program, but testing is common - arguably a practice that ran ahead of the evidence. Public and professional communication about PSA screening has been highly varied and potentially confusing for practitioners and patients alike. There has been much research and policy activity relating to PSA testing in recent years. Landmark randomised controlled trials have been reported; authorities - including the 2013 Prostate Cancer World Congress, the Prostate Cancer Foundation of Australia, Cancer Council Australia, and the National Health and Medical Research Council - have made or endorsed public statements and/or issued clinical practice guidelines; and the US Preventive Services Task Force is revising its recommendations. But disagreement continues. The contention is partly over what the new evidence means. It is also a result of different valuing and prioritisation of outcomes that are hard to compare: Prostate cancer deaths prevented (a small and disputed number); prevention of metastatic disease (somewhat more common); and side-effects of treatment such as incontinence, impotence and bowel trouble (more common again). A sizeable proportion of men diagnosed through PSA testing (somewhere between 20% and 50%) would never have had prostate cancer symptoms sufficient to prompt investigation; many of these men are older, with competing comorbidities. It is a complex picture.
Keyword Urology & Nephrology
Urology & Nephrology
UROLOGY & NEPHROLOGY
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Critical review of research, literature review, critical commentary
Collections: UQ Centre for Clinical Research Publications
HERDC Pre-Audit
Admin Only - UQCCR
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 2 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 3 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Tue, 15 Aug 2017, 00:09:26 EST by System User on behalf of Learning and Research Services (UQ Library)